drug · antibody
infliximab biosimilar
Marketedupdated 6mo agoby Xentria Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 44 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
targets
Tumor necrosis factor
all catalysts(6)
approval · 6
Apr 21, 2017
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Mar 21, 2019
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Jun 26, 2019
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Jan 27, 2022
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Dec 26, 2023
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Oct 28, 2025
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Trials studying infliximab biosimilar
- —Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
- —Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
- —Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
News(2)
- Celltrion picks up another Kaigene autoimmune antibody for up to $580.5MCelltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…fiercebiotech · 28d ago
- Hospital and pharmaceutical prices are smothering America’s businessesWorkers and employers are drowning in their health insurance premiums. The reason for that deluge: the health care industry’s high and inscrutable prices.stat · 1mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that